We are proud to announce our $10M ARPA-H award to develop ENDOinform™, a simple blood test that could dramatically reduce the 11-year average diagnosis journey. Learn more at aspirawh.com! #SprintforWomensHealth

This Thanksgiving, we’re thankful for healthcare professionals advancing women’s health and honor those affected by ovarian cancer and other gynecologic diseases. From all of us at Aspira Women’s Health, have a Thanksgiving filled with gratitude and hope. 🦃💐 #HappyThanksgiving

We’ve hit the first milestone of the ARPA-H $10M #SprintforWomensHealth Award, marking a major step in advancing non-invasive diagnostics for endometriosis. With $2M in funding, we’ve laid the groundwork for transformative innovation in women’s health. ir.aspirawh.com/press-release/…

Join our President, Dr. Sandra Milligan, at Cure Celebrates: ARPA-H’s Transformational Investments in Women’s Health! Honoring NY-area #SprintforWomensHealth winners with $113M awarded to 23 innovators. We Will Cure ARPA-H RSVP now: wewillcure.com/events/event/a…

Aspira Women’s Health has successfully completed the first milestone of the ARPA-H $10 million #SprintforWomensHealth Award. Our focus now shifts to the next milestone, expanding R&D capabilities, with completion targeted for early 2025. Read more: ir.aspirawh.com/press-release/…

We’re excited to be recognized at Amazon Web Services re:Invent 2024 as part of the ARPA-H #SprintforWomensHealth initiative. Check out the full article to learn more about how these groundbreaking projects are shaping the future of women’s health here: aws.amazon.com/blogs/publicse…

We’re proud to be part of the ARPA-H #SprintforWomensHealth initiative, leveraging Amazon Web Services technology to drive progress in gynecological health. Read the article to learn more about how AWS is helping us advance innovative solutions for women’s health: aws.amazon.com/blogs/publicse…

Join our ongoing endometriosis clinical study! We're working to advance the understanding and treatment of #endometriosis. Your patients may be eligible for our study. Email us at [email protected] to collaborate! #Endo #EndoResearch #EndometriosisResearch #ClinicalStudy

We are pleased to announce the appointment of Dr. Sandra Milligan as Interim CEO of Aspira Women’s Health. Her deep expertise and dedication to our mission make her well-equipped to lead us through this next chapter. Read the latest press release here: ir.aspirawh.com/press-release/…

Thank you, Nicole, for your dedication and lasting contributions to Aspira’s journey. Read more in the full press release here: ir.aspirawh.com/press-release/…

We are pleased to announce that Sandy Milligan, MD JD has stepped into the role of Interim CEO at Aspira Women's Health. Read the full press release to learn more about this important leadership transition here: ir.aspirawh.com/press-release/…

As we reflect on 2024 and look ahead to 2025, we're thrilled to continue our journey together, making a meaningful impact on women’s health. Wishing you a joyful holiday season and a new year filled with hope, health, and positive change. Stay tuned for our 2024 highlights! 🎉

From groundbreaking diagnostic tools to collaborations advancing women’s health, 2024 was a year of growth & progress. 🌟 Starting tomorrow, we’ll count down our Top 5 Moments of 2024—one highlight each day. Join us in celebrating these milestones as we look ahead to 2025!

Highlight #5: Honored as “Innovator of the Month” ✨ We are proud to have received the “Innovator of the Month” award from U.S. Senator Chris Murphy! This celebrates our commitment to women's health innovation as we move into 2025. Read more: murphy.senate.gov/newsroom/press…

Highlight #4: Expanding Our Collaboration for Women’s Health Aspira Women’s Health expanded its co-marketing and distribution collaboration with BioReference® to include OvaWatch® in New York and New Jersey. Read more about this expansion in our PR: ir.aspirawh.com/press-release/…

Highlight #3: Advancing Women’s Health Through Research Aspira Women’s Health published research showing that OvaWatch® can help stratify risk in patients with an adnexal mass, potentially reducing surgical backlogs and unnecessary referrals. Read more: ir.aspirawh.com/press-release/…

🌸 Empowering Women's Health 🌸 Aspira Women's Health is revolutionizing gynecologic care, starting with early detection and management of ovarian cancer. 💪✨ Transforming lives, one breakthrough at a time. Vince Caruso Watch the full interview here⬇⬇⬇ youtube.com/watch?v=PcQZMN…

Highlight #2: OvaWatch® Expansion Aspira Women’s Health received approval from NYSDOH for OvaWatch® and its longitudinal monitoring feature, reflecting our commitment to advanced ovarian health solutions. Read more: ir.aspirawh.com/press-release/…

Highlight #1: A $10 Million Dollar Step Toward Transforming Women’s Health Aspira Women’s Health secured a remarkable $10 million dollar award from the ARPA-H #SprintforWomensHealth initiative, marking a pivotal moment in 2024. Read more: ir.aspirawh.com/press-release/…

Does This Patient Really Need a Gyn Oncology Referral? Two blood tests improve risk in assessment after ovarian ultrasound. aspirawh.com/publication/do…